Vertex pauses diabetes cell therapy study following two patient deaths

Vertex has pressed pause on its Phase 1/2 study of its insulin-producing cell therapy for patients with type 1 diabetes following two patient deaths that the company said were unrelated to the drug. This is the second time Vertex’s progress on its diabetes drug has been paused.